Risk O
of O
transient O
hyperammonemic O
encephalopathy O
in O
cancer O
patients O
who O
received O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
with O
the O
complication O
of O
dehydration O
and O
infection O
. O

From O
1986 O
to O
1998 O
, O
29 O
cancer O
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic O
encephalopathy O
related O
to O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
were O
identified O
. O

From O
1986 O
to O
1998 O
, O
29 O
cancer O
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic O
encephalopathy O
related O
to O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
were O
identified O
. O

Higher O
plasma O
ammonium B
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia O
were O
seen O
in O
18 O
patients O
with O
bacterial O
infections O
( O
p O
= O
0 O
. O
003 O
and O
0 O
. O
0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 B
- I
FU I
( O
p O
= O
0 O
. O
0001 O
and O
< O
0 O
. O
0001 O
, O
respectively O
) O
. O

In O
conclusion O
, O
hyperammonemic O
encephalopathy O
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 B
- I
FU I
. O

It O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
infusion O
of O
5 B
- I
FU I
. O

The O
effects O
of O
quinine B
and O
4 B
- I
aminopyridine I
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
morphine B
in O
rats O
. O

The O
effects O
of O
two O
unselective O
potassium B
( O
K B
( O
+ O
) O
- O
) O
channel O
blockers O
, O
quinine B
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 B
- I
aminopyridine I
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
biphasic O
changes O
in O
motor O
activity O
induced O
by O
morphine B
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
Wistar O
rats O
. O

Quinine B
is O
known O
to O
block O
voltage O
- O
, O
calcium B
- O
and O
ATP B
- O
sensitive O
K B
( O
+ O
) O
- O
channels O
while O
4 B
- I
aminopyridine I
is O
known O
to O
block O
voltage O
- O
sensitive O
K B
( O
+ O
) O
- O
channels O
. O

In O
the O
counterbalanced O
method O
, O
quinine B
attenuated O
morphine B
- O
induced O
place O
preference O
, O
whereas O
4 B
- I
aminopyridine I
was O
ineffective O
. O

These O
results O
suggest O
the O
involvement O
of O
quinine B
- O
sensitive O
but O
not O
4 B
- I
aminopyridine I
- O
sensitive O
K B
( O
+ O
) O
- O
channels O
in O
morphine B
reward O
. O

It O
is O
also O
suggested O
that O
the O
blockade O
of O
K B
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine B
- O
induced O
hypoactivity O
whereas O
morphine B
- O
induced O
hyperactivity O
seems O
to O
be O
connected O
to O
both O
quinine B
- O
and O
4 B
- I
aminopyridine I
- O
sensitive O
K B
( O
+ O
) O
- O
channels O
. O

Sub O
- O
chronic O
inhibition O
of O
nitric B
- I
oxide I
synthesis O
modifies O
haloperidol B
- O
induced O
catalepsy O
and O
the O
number O
of O
NADPH B
- O
diaphorase O
neurons O
in O
mice O
. O

RATIONALE O
: O
NG B
- I
nitro I
- I
L I
- I
arginine I
( O
L B
- I
NOARG I
) O
, O
an O
inhibitor O
of O
nitric B
- I
oxide I
synthase O
( O
NOS O
) O
, O
induces O
catalepsy O
in O
mice O
. O

RATIONALE O
: O
NG B
- I
nitro I
- I
L I
- I
arginine I
( O
L B
- I
NOARG I
) O
, O
an O
inhibitor O
of O
nitric B
- I
oxide I
synthase O
( O
NOS O
) O
, O
induces O
catalepsy O
in O
mice O
. O

This O
effect O
undergoes O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub O
- O
chronic O
L B
- I
NOARG I
treatment O
. O

OBJECTIVES O
: O
To O
investigate O
the O
effects O
of O
subchronic O
L B
- I
NOARG I
treatment O
in O
haloperidol B
- O
induced O
catalepsy O
and O
the O
number O
of O
NOS O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

METHODS O
: O
Male O
albino O
Swiss O
mice O
were O
treated O
sub O
- O
chronically O
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
L B
- I
NOARG I
( O
40 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
haloperidol B
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

RESULTS O
: O
L B
- I
NOARG I
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
L B
- I
NOARG I
and O
of O
haloperidol B
- O
induced O
catalepsy O
. O

RESULTS O
: O
L B
- I
NOARG I
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
L B
- I
NOARG I
and O
of O
haloperidol B
- O
induced O
catalepsy O
. O

In O
contrast O
, O
there O
was O
a O
decrease O
in O
NADPH B
- O
d O
neuron O
number O
in O
the O
substantia O
nigra O
, O
pars O
compacta O
in O
both O
haloperidol B
- O
treated O
and O
L B
- I
NOARG I
- O
treated O
animals O
. O

We O
compared O
the O
toxicity O
of O
NS O
- O
718 O
with O
that O
of O
Fungizone B
( O
amphotericin B
B I
- I
sodium I
deoxycholate I
; O
D B
- I
AmB I
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin B
B I
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Incubation O
with O
NS O
- O
718 O
resulted O
in O
significantly O
less O
damage O
of O
cultured O
human O
renal O
proximal O
tubular O
epithelial O
cells O
compared O
with O
D B
- I
AmB I
. O

Serum O
blood O
urea B
and O
creatinine B
concentrations O
increased O
significantly O
in O
rats O
given O
an O
iv O
infusion O
of O
D B
- I
AmB I
3 O
mg O
/ O
kg O
but O
not O
in O
those O
given O
the O
same O
dose O
of O
NS O
- O
718 O
. O

Histopathological O
examination O
of O
the O
kidney O
showed O
tubular O
necrosis O
in O
D B
- I
AmB I
- O
treated O
rats O
but O
no O
change O
in O
NS O
- O
718 O
- O
treated O
rats O
. O

Amphotericin B
B I
concentrations O
in O
the O
kidney O
in O
NS O
- O
718 O
- O
treated O
rats O
were O
higher O
than O
those O
in O
D B
- I
AmB I
- O
treated O
rats O
. O

Effective O
compounds O
included O
norleucine B
, O
norvaline B
, O
glutamate B
, O
epsilon B
- I
aminocaproate I
, O
methionine B
, O
and O
leucine B
. O

High O
- O
dose O
5 B
- I
fluorouracil I
/ O
folinic B
acid I
in O
combination O
with O
three O
- O
weekly O
mitomycin B
C I
in O
the O
treatment O
of O
advanced O
gastric O
cancer O
. O

BACKGROUND O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
and O
folinic B
acid I
( O
FA B
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric O
cancer O
( O
AGC O
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity O
. O

BACKGROUND O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
and O
folinic B
acid I
( O
FA B
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric O
cancer O
( O
AGC O
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity O
. O

In O
a O
previous O
phase O
II O
study O
with O
3 O
- O
weekly O
bolus O
5 B
- I
FU I
, O
FA B
and O
mitomycin B
C I
( O
MMC B
) O
we O
found O
a O
low O
toxicity O
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
ELF O
, O
FAM O
or O
FAMTX O
, O
and O
a O
promising O
median O
overall O
survival O
. O

In O
order O
to O
improve O
this O
MMC B
- O
dependent O
schedule O
we O
initiated O
a O
phase O
II O
study O
with O
high O
- O
dose O
5 B
- I
FU I
/ O
FA B
and O
3 O
- O
weekly O
bolus O
MMC B
. O

PATIENTS O
AND O
METHODS O
: O
From O
February O
, O
1998 O
to O
September O
, O
2000 O
we O
recruited O
33 O
patients O
with O
AGC O
to O
receive O
weekly O
24 O
- O
hour O
5 B
- I
FU I
2 O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
preceded O
by O
2 O
- O
hour O
FA B
500 O
mg O
/ O
m O
( O
2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O

CONCLUSIONS O
: O
High O
- O
dose O
5 B
- I
FU I
/ O
FA B
/ O
MMC B
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
AGC O
( O
objective O
response O
rate O
54 O
. O
6 O
% O
) O
. O

Moreover O
, O
all O
adenosine B
receptor O
agonists O
: O
2 B
- I
p I
- I
( I
2 I
- I
carboxyethyl I
) I
phenethylamino I
- I
5 I
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
CGS B
21680 I
) O
, O
A2A O
receptor O
agonist O
, O
N6 B
- I
cyclopentyladenosine I
( O
CPA B
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
NECA B
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine B
- O
induced O
locomotor O
activity O
. O

CPT B
( O
8 B
- I
cyclopentyltheophylline I
) O
- O
- O
A1 O
receptor O
antagonist O
, O
did O
not O
show O
any O
influence O
in O
this O
test O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B
acid I
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
but O
suppressed O
the O
synthesis O
of O
gamma B
- I
aminobutyric I
acid I
and O
acetylcholine B
in O
mouse O
brain O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B
acid I
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
but O
suppressed O
the O
synthesis O
of O
gamma B
- I
aminobutyric I
acid I
and O
acetylcholine B
in O
mouse O
brain O
. O

Pharmacology O
of O
gamma B
- I
aminobutyric I
acidA I
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta B
- I
carboline I
derivative O
abecarnil B
. O

In O
rodents O
, O
the O
effect O
of O
the O
beta B
- I
carboline I
derivative O
isopropyl B
- I
6 I
- I
benzyloxy I
- I
4 I
- I
methoxymethyl I
- I
beta I
- I
carboline I
- I
3 I
- I
carboxylate I
( O
abecarrnil B
) O
, O
a O
new O
ligand O
for O
benzodiazepine B
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
A O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta B
- I
carboline I
reduced O
markedly O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
and O
the O
convulsions O
induced O
by O
isoniazid B
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

We O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic O
anemia O
crisis O
induced O
by O
trimethoprim B
- I
sulfomethoxazole I
, O
resulting O
in O
cerebral O
anoxia O
leading O
to O
permanent O
damage O
. O

Ultrastructural O
damage O
and O
levels O
of O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
4HNE B
) O
- O
protein O
adducts O
and O
3 B
- I
nitrotyrosine I
( O
3NT B
) O
were O
analyzed O
. O

Effects O
of O
the O
antidepressant O
trazodone B
, O
a O
5 B
- I
HT I
2A O
/ O
2C O
receptor O
antagonist O
, O
on O
dopamine B
- O
dependent O
behaviors O
in O
rats O
. O

RATIONALE O
: O
5 B
- I
Hydroxytryptamine I
, O
via O
stimulation O
of O
5 B
- I
HT I
2C O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5 B
- I
HT I
2A O
receptors O
enhances O
stimulated O
DAergic O
neurotransmission O
. O

RATIONALE O
: O
5 B
- I
Hydroxytryptamine I
, O
via O
stimulation O
of O
5 B
- I
HT I
2C O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5 B
- I
HT I
2A O
receptors O
enhances O
stimulated O
DAergic O
neurotransmission O
. O

RATIONALE O
: O
5 B
- I
Hydroxytryptamine I
, O
via O
stimulation O
of O
5 B
- I
HT I
2C O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5 B
- I
HT I
2A O
receptors O
enhances O
stimulated O
DAergic O
neurotransmission O
. O

The O
antidepressant O
trazodone B
is O
a O
5 B
- I
HT I
2A O
/ O
2C O
receptor O
antagonist O
. O

Furthermore O
, O
at O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
, O
trazodone B
blocks O
5 B
- I
HT I
2A O
and O
5 B
- I
HT I
2C O
receptors O
. O

Furthermore O
, O
at O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
, O
trazodone B
blocks O
5 B
- I
HT I
2A O
and O
5 B
- I
HT I
2C O
receptors O
. O

We O
suggest O
that O
trazodone B
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 B
- I
HT I
2C O
receptors O
, O
releases O
the O
nigrostriatal O
DAergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 B
- I
HT I
, O
and O
thereby O
potentiates O
dexamphetamine B
stereotypy O
and O
antagonizes O
haloperidol B
catalepsy O
. O

We O
suggest O
that O
trazodone B
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 B
- I
HT I
2C O
receptors O
, O
releases O
the O
nigrostriatal O
DAergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 B
- I
HT I
, O
and O
thereby O
potentiates O
dexamphetamine B
stereotypy O
and O
antagonizes O
haloperidol B
catalepsy O
. O

The O
antiinfective O
group O
of O
drugs O
was O
the O
more O
frequently O
incriminated O
, O
amoxicillin B
- I
clavulanate I
accounting O
for O
the O
12 O
. O
8 O
% O
of O
the O
whole O
series O
. O

Amoxicillin B
- I
clavulanate I
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
DILI O
. O

Morphological O
evaluation O
of O
the O
effect O
of O
d B
- I
ribose I
on O
adriamycin B
- O
evoked O
cardiotoxicity O
in O
rats O
. O

The O
influence O
of O
d B
- I
ribose I
on O
adriamycin B
- O
induced O
myocardiopathy O
in O
rats O
was O
studied O
. O

D B
- I
ribose I
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
ADR B
cardiotoxicity O
. O

5 B
- I
Fluorouracil I
cardiotoxicity O
induced O
by O
alpha B
- I
fluoro I
- I
beta I
- I
alanine I
. O

Cardiotoxicity O
is O
a O
rare O
complication O
occurring O
during O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
treatment O
for O
malignancies O
. O

Cardiotoxicity O
is O
a O
rare O
complication O
occurring O
during O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
treatment O
for O
malignancies O
. O

We O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 B
- I
FU I
- O
induced O
cardiotoxicity O
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha B
- I
fluoro I
- I
beta I
- I
alanine I
( O
FBAL B
) O
was O
observed O
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 B
- I
FU I
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial O
pain O
with O
right O
bundle O
branch O
block O
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL B
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Both O
the O
precordial O
pain O
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5 B
- I
FU I
. O

As O
the O
precordial O
pain O
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 B
- I
FU I
- O
induced O
cardiotoxicity O
, O
the O
administration O
of O
5 B
- I
FU I
was O
abandoned O
. O

As O
the O
precordial O
pain O
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 B
- I
FU I
- O
induced O
cardiotoxicity O
, O
the O
administration O
of O
5 B
- I
FU I
was O
abandoned O
. O

Instead O
, O
oral O
administration O
of O
S O
- O
1 O
( O
a O
derivative O
of O
5 B
- I
FU I
) O
, O
at O
200 O
mg O
/ O
day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
S O
- O
1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine B
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5 B
- I
FU I
into O
FBAL B
. O

Instead O
, O
oral O
administration O
of O
S O
- O
1 O
( O
a O
derivative O
of O
5 B
- I
FU I
) O
, O
at O
200 O
mg O
/ O
day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
S O
- O
1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine B
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5 B
- I
FU I
into O
FBAL B
. O

The O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
FBAL B
is O
related O
to O
5 B
- I
FU I
- O
induced O
cardiotoxicity O
. O

S O
- O
1 O
may O
be O
administered O
safely O
to O
patients O
with O
5 B
- I
FU I
- O
induced O
cardiotoxicity O
. O

Acute O
encephalopathy O
and O
cerebral O
vasospasm O
after O
multiagent O
chemotherapy O
including O
PEG B
- I
asparaginase I
and O
intrathecal O
cytarabine B
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukemia O
. O

Piperacillin B
/ I
tazobactam I
- O
induced O
seizure O
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end O
- O
stage O
renal O
disease O
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor O
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion O
, O
and O
2 O
episodes O
of O
generalized O
tonic O
- O
clonic O
seizure O
( O
GTCS O
) O
after O
5 O
doses O
of O
piperacillin B
/ I
tazobactam I
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis O
with O
secondary O
infection O
. O

Despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
GTCS O
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin B
/ I
tazobactam I
. O

He O
then O
presented O
to O
the O
emergency O
department O
feeling O
quite O
ill O
and O
was O
found O
to O
have O
a O
blood B
urea I
nitrogen I
( O
BUN B
) O
concentration O
of O
of O
147 O
mg O
/ O
dl O
, O
creatinine B
of O
15 O
. O
3 O
mg O
/ O
dl O
and O
serum O
potassium B
of O
8 O
. O
7 O
mEq O
/ O
l O
. O

Increased O
vulnerability O
to O
6 B
- I
hydroxydopamine I
lesion O
and O
reduced O
development O
of O
dyskinesias O
in O
mice O
lacking O
CB1 O
cannabinoid O
receptors O
. O

Motor O
impairment O
, O
dopamine B
( O
DA B
) O
neuronal O
activity O
and O
proenkephalin B
( O
PENK B
) O
gene O
expression O
in O
the O
caudate O
- O
putamen O
( O
CPu O
) O
were O
measured O
in O
6 B
- I
OHDA I
- O
lesioned O
and O
treated O
( O
L B
- I
DOPA I
+ I
benserazide I
) O
CB1 O
KO O
and O
WT O
mice O
. O

A O
lesion O
induced O
by O
6 B
- I
OHDA I
produced O
more O
severe O
motor O
deterioration O
in O
CB1 O
KO O
mice O
accompanied O
by O
more O
loss O
of O
DA B
neurons O
and O
increased O
PENK B
gene O
expression O
in O
the O
CPu O
. O

The O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
CB1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
DA B
lesion O
, O
and O
reduced O
L B
- I
DOPA I
- O
induced O
dyskinesias O
. O

These O
results O
suggest O
that O
activation O
of O
CB1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
L B
- I
DOPA I
- O
induced O
dyskinesias O
. O

Fluoxetine B
improves O
the O
memory O
deficits O
caused O
by O
the O
chemotherapy O
agent O
5 B
- I
fluorouracil I
. O

A O
widely O
used O
chemotherapeutic O
agent O
, O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
, O
readily O
crosses O
the O
blood O
- O
brain O
barrier O
and O
so O
could O
have O
a O
direct O
effect O
on O
brain O
function O
. O

A O
widely O
used O
chemotherapeutic O
agent O
, O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
, O
readily O
crosses O
the O
blood O
- O
brain O
barrier O
and O
so O
could O
have O
a O
direct O
effect O
on O
brain O
function O
. O

In O
this O
investigation O
the O
behavioural O
effects O
of O
chronic O
( O
two O
week O
) O
treatment O
with O
5 B
- I
FU I
and O
( O
three O
weeks O
) O
with O
Fluoxetine B
either O
separately O
or O
in O
combination O
with O
5 B
- I
FU I
were O
tested O
on O
adult O
Lister O
hooded O
rats O
. O

In O
this O
investigation O
the O
behavioural O
effects O
of O
chronic O
( O
two O
week O
) O
treatment O
with O
5 B
- I
FU I
and O
( O
three O
weeks O
) O
with O
Fluoxetine B
either O
separately O
or O
in O
combination O
with O
5 B
- I
FU I
were O
tested O
on O
adult O
Lister O
hooded O
rats O
. O

Behavioural O
effects O
were O
tested O
using O
a O
context O
dependent O
conditioned O
emotional O
response O
test O
( O
CER O
) O
which O
showed O
that O
animals O
treated O
with O
5 B
- I
FU I
had O
a O
significant O
reduction O
in O
freezing O
time O
compared O
to O
controls O
. O

Animals O
treated O
only O
with O
5 B
- I
FU I
showed O
significant O
deficits O
in O
their O
ability O
to O
carry O
out O
the O
OLR O
task O
but O
co O
administration O
of O
Fluoxetine B
improved O
their O
performance O
. O

5 B
- I
FU I
chemotherapy O
caused O
a O
significant O
reduction O
in O
the O
number O
of O
proliferating O
cells O
in O
the O
sub O
granular O
zone O
of O
the O
dentate O
gyrus O
compared O
to O
controls O
. O

This O
reduction O
was O
eliminated O
when O
Fluoxetine B
was O
co O
administered O
with O
5 B
- I
FU I
. O

These O
findings O
suggest O
that O
5 B
- I
FU I
can O
negatively O
affect O
both O
cell O
proliferation O
and O
hippocampal O
dependent O
working O
memory O
and O
that O
these O
deficits O
can O
be O
reversed O
by O
the O
simultaneous O
administration O
of O
the O
antidepressant O
Fluoxetine B
. O

The O
treatment O
of O
HIT O
mandates O
an O
immediate O
cessation O
of O
all O
heparin B
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct B
thrombin I
inhibitor I
. O

Direct B
thrombin I
inhibitors I
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin B
in O
patients O
with O
a O
history O
of O
HIT O
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

Drug O
studies O
using O
the O
indirect O
antiglobulin O
test O
were O
strongly O
positive O
with O
trimethoprim B
and O
trimethoprim B
- I
sulfamethoxazole I
but O
negative O
with O
sulfamethoxazole B
. O

Nitric B
oxide I
( O
NO B
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
L B
- I
arginine I
, O
precursor O
of O
NO B
syntheses O
( O
NOS O
) O
, O
and O
L B
- I
NAME I
( O
NOS O
inhibitor O
) O
observed O
in O
different O
epilepsy O
models O
. O

Nitric B
oxide I
( O
NO B
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
L B
- I
arginine I
, O
precursor O
of O
NO B
syntheses O
( O
NOS O
) O
, O
and O
L B
- I
NAME I
( O
NOS O
inhibitor O
) O
observed O
in O
different O
epilepsy O
models O
. O

The O
administration O
of O
L B
- I
arginine I
( O
600 O
, O
800 O
and O
1000 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
in O
dose O
- O
dependent O
manner O
significantly O
increased O
convulsion O
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion O
elicited O
by O
lower O
lindane B
dose O
( O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

On O
the O
contrary O
, O
pretreatment O
with O
L B
- I
NAME I
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
decreased O
convulsion O
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion O
following O
injection O
with O
a O
convulsive O
dose O
of O
lindane B
( O
8 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

EEG O
analyses O
showed O
increase O
of O
number O
and O
duration O
of O
ictal O
periods O
in O
EEG O
of O
rats O
receiving O
l B
- I
arginine I
prior O
to O
lindane B
and O
decrease O
of O
this O
number O
in O
rats O
pretreated O
with O
L B
- I
NAME I
. O

EEG O
analyses O
showed O
increase O
of O
number O
and O
duration O
of O
ictal O
periods O
in O
EEG O
of O
rats O
receiving O
l B
- I
arginine I
prior O
to O
lindane B
and O
decrease O
of O
this O
number O
in O
rats O
pretreated O
with O
L B
- I
NAME I
. O

In O
spite O
of O
the O
fact O
that O
TSPA B
is O
a O
useful O
IT O
agent O
, O
its O
combination O
with O
MTX B
, O
ara B
- I
C I
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity O
. O

An O
alternative O
source O
of O
energy O
is O
d B
- I
galactose I
( O
the O
C O
- O
4 O
- O
epimer O
of O
d B
- I
glucose I
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin O
- O
independent O
GLUT3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose B
via O
the O
Leloir O
pathway O
. O

An O
alternative O
source O
of O
energy O
is O
d B
- I
galactose I
( O
the O
C O
- O
4 O
- O
epimer O
of O
d B
- I
glucose I
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin O
- O
independent O
GLUT3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose B
via O
the O
Leloir O
pathway O
. O

An O
investigation O
of O
the O
pattern O
of O
kidney O
injury O
in O
HIV O
- O
positive O
persons O
exposed O
to O
tenofovir B
disoproxil I
fumarate I
: O
an O
examination O
of O
a O
large O
population O
database O
( O
MHRA O
database O
) O
. O

We O
undertook O
a O
descriptive O
analysis O
of O
Yellow O
Card O
records O
of O
407 O
HIV O
- O
positive O
persons O
taking O
tenofovir B
disoproxil I
fumarate I
( O
TDF B
) O
as O
part O
of O
their O
antiretroviral O
therapy O
regimen O
and O
submitted O
to O
the O
Medicines O
and O
Healthcare O
Products O
Regulatory O
Agency O
( O
MHRA O
) O
with O
suspected O
kidney O
adverse O
effects O
. O

Histamine B
antagonists O
and O
d B
- I
tubocurarine I
- O
induced O
hypotension O
in O
cardiac O
surgical O
patients O
. O

Hemodynamic O
effects O
and O
histamine B
release O
by O
bolus O
injection O
of O
0 O
. O
35 O
mg O
/ O
kg O
of O
d B
- I
tubocurarine I
were O
studied O
in O
24 O
patients O
. O

H1 O
- O
and O
H2 O
- O
histamine B
antagonists O
or O
placebo O
were O
given O
before O
dosing O
with O
d B
- I
tubocurarine I
in O
a O
randomized O
double O
- O
blind O
fashion O
to O
four O
groups O
: O
group O
1 O
- O
- O
placebo O
; O
group O
2 O
- O
- O
cimetidine B
, O
4 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
group O
3 O
- O
- O
chlorpheniramine B
, O
0 O
. O
1 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
and O
group O
4 O
- O
- O
cimetidine B
plus O
chlorpheniramine B
. O

Histamine B
release O
occurred O
in O
most O
patients O
, O
the O
highest O
level O
2 O
minutes O
after O
d B
- I
tubocurarine I
dosing O
. O

These O
data O
demonstrate O
that O
the O
hemodynamic O
changes O
associated O
with O
d B
- I
tubocurarine I
dosing O
are O
only O
partially O
explained O
by O
histamine B
release O
. O

Cholecystokinin B
- I
octapeptide I
restored O
morphine B
- O
induced O
hippocampal O
long O
- O
term O
potentiation O
impairment O
in O
rats O
. O

Cholecystokinin B
- I
octapeptide I
( O
CCK B
- I
8 I
) O
, O
which O
is O
a O
typical O
brain O
- O
gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

Cholecystokinin B
- I
octapeptide I
( O
CCK B
- I
8 I
) O
, O
which O
is O
a O
typical O
brain O
- O
gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

We O
have O
previously O
reported O
that O
CCK B
- I
8 I
significantly O
alleviated O
morphine B
- O
induced O
amnesia O
and O
reversed O
spine O
density O
decreases O
in O
the O
CA1 O
region O
of O
the O
hippocampus O
in O
morphine B
- O
treated O
animals O
. O

Here O
, O
we O
investigated O
the O
effects O
of O
CCK B
- I
8 I
on O
long O
- O
term O
potentiation O
( O
LTP O
) O
in O
the O
lateral O
perforant O
path O
( O
LPP O
) O
- O
granule O
cell O
synapse O
of O
rat O
dentate O
gyrus O
( O
DG O
) O
in O
acute O
saline O
or O
morphine B
- O
treated O
rats O
. O

Acute O
morphine B
( O
30mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
treatment O
significantly O
attenuated O
hippocampal O
LTP O
and O
CCK B
- I
8 I
( O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
restored O
the O
amplitude O
of O
PS O
that O
was O
attenuated O
by O
morphine B
injection O
. O

Furthermore O
, O
microinjection O
of O
CCK B
- I
8 I
( O
0 O
. O
1 O
and O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
also O
significantly O
augmented O
hippocampal O
LTP O
in O
saline O
- O
treated O
( O
1ml O
/ O
kg O
, O
s O
. O
c O
. O
) O
rats O
. O

Pre O
- O
treatment O
of O
the O
CCK2 O
receptor O
antagonist O
L O
- O
365 O
, O
260 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
reversed O
the O
effects O
of O
CCK B
- I
8 I
, O
but O
the O
CCK1 O
receptor O
antagonist O
L O
- O
364 O
, O
718 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
did O
not O
. O

The O
present O
results O
demonstrate O
that O
CCK B
- I
8 I
attenuates O
the O
effect O
of O
morphine B
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK B
- I
8 I
on O
morphine B
- O
induced O
memory O
impairment O
. O

The O
present O
results O
demonstrate O
that O
CCK B
- I
8 I
attenuates O
the O
effect O
of O
morphine B
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK B
- I
8 I
on O
morphine B
- O
induced O
memory O
impairment O
. O

All O
of O
the O
patients O
' O
plasma O
blood B
urea I
nitrogen I
( O
BUN B
) O
and O
creatinine B
levels O
were O
measured O
on O
the O
second O
and O
seventh O
day O
after O
the O
administration O
of O
intravenous O
contrast B
material O
. O

Lindane B
( O
gamma B
- I
hexachlorocyclohexane I
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic O
effects O
. O

BACKGROUND O
: O
S B
- I
53482 I
and O
S B
- I
23121 I
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality O
, O
teratogenicity O
( O
mainly O
ventricular O
septal O
defects O
and O
wavy O
ribs O
) O
, O
and O
growth O
retardation O
in O
rats O
in O
conventional O
oral O
developmental O
toxicity O
studies O
. O

BACKGROUND O
: O
S B
- I
53482 I
and O
S B
- I
23121 I
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality O
, O
teratogenicity O
( O
mainly O
ventricular O
septal O
defects O
and O
wavy O
ribs O
) O
, O
and O
growth O
retardation O
in O
rats O
in O
conventional O
oral O
developmental O
toxicity O
studies O
. O

METHODS O
: O
S B
- I
53482 I
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg O
/ O
kg O
during O
organogenesis O
, O
and O
S B
- I
23121 I
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg O
/ O
kg O
( O
the O
maximum O
applicable O
dose O
level O
) O
. O

METHODS O
: O
S B
- I
53482 I
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg O
/ O
kg O
during O
organogenesis O
, O
and O
S B
- I
23121 I
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg O
/ O
kg O
( O
the O
maximum O
applicable O
dose O
level O
) O
. O

RESULTS O
: O
Dermal O
exposure O
of O
rats O
to O
S B
- I
53482 I
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity O
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

Dermal O
administration O
of O
S B
- I
23121 I
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic O
death O
and O
ventricular O
septal O
defect O
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S B
- I
23121 I
. O

Dermal O
administration O
of O
S B
- I
23121 I
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic O
death O
and O
ventricular O
septal O
defect O
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S B
- I
23121 I
. O

CONCLUSIONS O
: O
Based O
on O
the O
results O
, O
S B
- I
53482 I
and O
S B
- I
23121 I
were O
teratogenic O
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

CONCLUSIONS O
: O
Based O
on O
the O
results O
, O
S B
- I
53482 I
and O
S B
- I
23121 I
were O
teratogenic O
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

Anticonvulsant O
actions O
of O
MK B
- I
801 I
on O
the O
lithium B
- O
pilocarpine B
model O
of O
status O
epilepticus O
in O
rats O
. O

MK B
- I
801 I
, O
a O
noncompetitive O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure O
models O
, O
coadministration O
of O
lithium B
and O
pilocarpine B
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine B
alone O
. O

First O
, O
pretreatment O
with O
MK B
- I
801 I
produced O
an O
effective O
and O
dose O
- O
dependent O
anticonvulsant O
action O
with O
the O
lithium B
- O
pilocarpine B
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine B
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures O
in O
these O
two O
models O
. O

Second O
, O
the O
anticonvulsant O
effect O
of O
MK B
- I
801 I
in O
the O
lithium B
- O
pilocarpine B
model O
only O
occurred O
after O
initial O
periods O
of O
seizure O
activity O
. O

This O
observation O
is O
suggested O
to O
be O
an O
in O
vivo O
demonstration O
of O
the O
conclusion O
derived O
from O
in O
vitro O
experiments O
that O
MK B
- I
801 I
binding O
requires O
agonist O
- O
induced O
opening O
of O
the O
channel O
sites O
of O
the O
NMDA B
receptor O
. O

Administration O
of O
MK B
- I
801 I
30 O
or O
60 O
min O
after O
pilocarpine B
, O
i O
. O
e O
. O
, O
during O
status O
epilepticus O
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure O
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

In O
addition O
, O
the O
patients O
received O
fentanyl B
and O
d B
- I
tubocurarine I
. O

Pharmacology O
of O
ACC B
- I
9653 I
( O
phenytoin B
prodrug O
) O
. O

ACC B
- I
9653 I
, O
the O
disodium B
phosphate I
ester I
of O
3 B
- I
hydroxymethyl I
- I
5 I
, I
5 I
- I
diphenylhydantoin I
, O
is O
a O
prodrug O
of O
phenytoin B
with O
advantageous O
physicochemical O
properties O
. O

ACC B
- I
9653 I
, O
the O
disodium B
phosphate I
ester I
of O
3 B
- I
hydroxymethyl I
- I
5 I
, I
5 I
- I
diphenylhydantoin I
, O
is O
a O
prodrug O
of O
phenytoin B
with O
advantageous O
physicochemical O
properties O
. O

ACC B
- I
9653 I
is O
rapidly O
converted O
enzymatically O
to O
phenytoin B
in O
vivo O
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
equivalent O
anticonvulsant O
activity O
against O
seizures O
induced O
by O
maximal O
electroshock O
( O
MES O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

The O
ED50 O
doses O
were O
16 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
ACC B
- I
9653 I
and O
8 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
phenytoin B
sodium I
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
similar O
antiarrhythmic O
activity O
against O
ouabain B
- O
induced O
ventricular O
tachycardia O
in O
anesthetized O
dogs O
. O

The O
total O
doses O
of O
ACC B
- I
9653 I
or O
phenytoin B
sodium I
necessary O
to O
convert O
the O
arrhythmia O
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

In O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
ACC B
- I
9653 I
( O
31 O
mg O
/ O
kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin B
sodium I
( O
21 O
mg O
/ O
kg O
) O
. O

The O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
( O
LVdP O
/ O
dt O
) O
. O

Acute O
toxicity O
studies O
of O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

Importantly O
, O
the O
local O
irritation O
of O
ACC B
- I
9653 I
was O
markedly O
less O
than O
phenytoin B
sodium I
following O
i O
. O
m O
. O
administration O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines B
with O
different O
potencies O
as O
adenosine B
antagonists O
8 B
- I
phenyltheophylline I
, O
theophylline B
and O
enprofylline B
, O
were O
examined O
in O
rats O
developing O
acute O
renal O
failure O
after O
4 O
daily O
injections O
of O
gentamicin B
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Differential O
effects O
of O
1 B
, I
4 I
- I
dihydropyridine I
calcium B
channel I
blockers I
: O
therapeutic O
implications O
. O

Clinical O
applications O
of O
calcium B
channel I
blockers I
parallel O
their O
tissue O
selectivity O
. O

In O
contrast O
to O
verapamil B
and O
diltiazem B
, O
which O
are O
roughly O
equipotent O
in O
their O
actions O
on O
the O
heart O
and O
vascular O
smooth O
muscle O
, O
the O
dihydropyridine B
calcium B
channel I
blockers I
are O
a O
group O
of O
potent O
peripheral O
vasodilator O
agents O
that O
exert O
minimal O
electrophysiologic O
effects O
on O
cardiac O
nodal O
or O
conduction O
tissue O
. O

Additional O
members O
of O
this O
group O
of O
calcium B
channel I
blockers I
have O
been O
studied O
for O
a O
variety O
of O
indications O
for O
which O
they O
may O
offer O
advantages O
over O
current O
therapy O
. O

In O
general O
, O
the O
dihydropyridine B
calcium B
channel I
blockers I
are O
usually O
well O
tolerated O
, O
with O
headache O
, O
facial O
flushing O
, O
palpitations O
, O
edema O
, O
nausea O
, O
anorexia O
, O
and O
dizziness O
being O
the O
more O
common O
adverse O
effects O
. O

An O
experimental O
model O
of O
focal O
segmental O
glomerular O
sclerosis O
( O
FSGS O
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin B
- I
aminonucleoside I
( O
AMNS B
) O
and O
protamine B
sulfate I
( O
PS B
) O
. O

Hypotension O
as O
a O
manifestation O
of O
cardiotoxicity O
in O
three O
patients O
receiving O
cisplatin B
and O
5 B
- I
fluorouracil I
. O

Cardiac O
symptoms O
, O
including O
hypotension O
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal O
carcinoma O
while O
being O
treated O
with O
cisplatin B
( O
CDDP B
) O
and O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
. O

Cardiac O
symptoms O
, O
including O
hypotension O
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal O
carcinoma O
while O
being O
treated O
with O
cisplatin B
( O
CDDP B
) O
and O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
. O

The O
presentation O
and O
cardiac O
evaluation O
( O
hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5 B
- I
FU I
cardiotoxicity O
that O
may O
be O
influenced O
by O
CDDP B
. O

Furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 B
- I
HT I
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 B
, I
7 I
- I
dihydroxytryptamine I
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac O
responses O
to O
clonidine B
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

Improvement O
by O
denopamine B
( O
TA B
- I
064 I
) O
of O
pentobarbital B
- O
induced O
cardiac O
failure O
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

The O
role O
of O
p B
- I
aminophenol I
in O
acetaminophen B
- O
induced O
nephrotoxicity O
: O
effect O
of O
bis B
( I
p I
- I
nitrophenyl I
) I
phosphate I
on O
acetaminophen B
and O
p B
- I
aminophenol I
nephrotoxicity O
and O
metabolism O
in O
Fischer O
344 O
rats O
. O

The O
role O
of O
p B
- I
aminophenol I
in O
acetaminophen B
- O
induced O
nephrotoxicity O
: O
effect O
of O
bis B
( I
p I
- I
nitrophenyl I
) I
phosphate I
on O
acetaminophen B
and O
p B
- I
aminophenol I
nephrotoxicity O
and O
metabolism O
in O
Fischer O
344 O
rats O
. O

Recently O
, O
p B
- I
aminophenol I
( O
PAP B
) O
, O
a O
known O
potent O
nephrotoxicant O
, O
was O
identified O
as O
a O
metabolite O
of O
APAP B
in O
F344 O
rats O
. O

Epsilon B
aminocaproic I
acid I
( O
EACA B
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid O
hemorrhage O
( O
SAH O
) O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B
octapeptide I
sulphate O
ester O
( O
CCK B
- I
8 I
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B
octapeptide I
( O
CCK B
- I
8 I
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin B
in O
mice O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B
octapeptide I
sulphate O
ester O
( O
CCK B
- I
8 I
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B
octapeptide I
( O
CCK B
- I
8 I
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin B
in O
mice O
. O

The O
analogues O
CCK B
- I
8 I
- O
SE O
and O
CCK B
- I
8 I
- O
NS O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein B
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
CCK B
- I
8 I
- O
NS O
. O

The O
analogues O
CCK B
- I
8 I
- O
SE O
and O
CCK B
- I
8 I
- O
NS O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein B
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
CCK B
- I
8 I
- O
NS O
. O

The O
analogues O
CCK B
- I
8 I
- O
SE O
and O
CCK B
- I
8 I
- O
NS O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein B
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
CCK B
- I
8 I
- O
NS O
. O

Experiments O
with O
analogues O
and O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
demonstrated O
that O
the O
effectiveness O
of O
the O
beta O
- O
alanyl O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
were O
enhanced O
and O
that O
they O
were O
equipotent O
with O
CCK B
- I
8 I
- O
SE O
. O

Of O
the O
CCK O
- O
2 O
- O
8 O
analogues O
, O
Ser O
( O
SO3H O
) O
7 O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Thr O
( O
SO3H O
) O
7 O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Hyp O
( O
SO3H O
) O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
were O
slightly O
more O
active O
than O
CCK B
- I
8 I
- O
SE O
. O

Male O
rats O
received O
the O
noradrenaline B
neurotoxin O
DSP4 B
( O
50 O
mg O
/ O
kg O
) O
7 O
days O
prior O
to O
injection O
of O
D B
- I
amphetamine I
( O
10 O
or O
40 O
mumol O
/ O
kg O
i O
. O
p O
. O
) O
. O

The O
hyperactivity O
induced O
by O
D B
- I
amphetamine I
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
DSP4 B
pretreatment O
. O

Treatment O
of O
ovarian O
cancer O
with O
a O
combination O
of O
cis B
- I
platinum I
, O
adriamycin B
, O
cyclophosphamide B
and O
hexamethylmelamine B
. O

The O
actions O
of O
fenoterol B
- I
hydrobromide I
, O
ritodrin B
- I
HCl I
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double O
- O
blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

The O
actions O
of O
fenoterol B
- I
hydrobromide I
, O
ritodrin B
- I
HCl I
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double O
- O
blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

After O
the O
end O
of O
fenoterol B
- I
hydrobromide I
infusion O
, O
tremor O
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin B
- I
HCl I
infusion O
. O

After O
the O
end O
of O
fenoterol B
- I
hydrobromide I
infusion O
, O
tremor O
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin B
- I
HCl I
infusion O
. O

Comparative O
study O
: O
Endografine B
( O
diatrizoate B
) O
, O
Vasurix B
polyvidone I
( O
acetrizoate B
) O
, O
Dimer B
- I
X I
( O
iocarmate B
) O
and O
Hexabrix B
( O
ioxaglate B
) O
in O
hysterosalpingography O
. O

Side O
effects O
of O
hysterosalpingography O
with O
Dimer B
- I
X I
, O
Hexabrix B
, O
Vasurix B
polyvidone I
and O
Endografine B
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

The O
Dimer B
- I
X I
group O
had O
a O
higher O
incidence O
of O
nausea O
and O
dizziness O
. O

Medial O
changes O
in O
arterial O
spasm O
induced O
by O
L B
- I
norepinephrine I
. O

In O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
L B
- I
norepinephrine I
produced O
many O
cell O
- O
to O
- O
cell O
hernias O
within O
15 O
minutes O
. O

A O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim B
- I
sulfamethoxazole I
, O
trimethoprim B
, O
and O
cephalexin B
for O
uncommon O
serious O
drug O
toxicity O
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim B
- I
sulfamethoxazole I
( O
TMP B
- I
SMZ I
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim B
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin B
, O
to O
estimate O
the O
risk O
of O
serious O
liver O
, O
blood O
, O
skin O
, O
and O
renal O
disorders O
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim B
- I
sulfamethoxazole I
( O
TMP B
- I
SMZ I
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim B
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin B
, O
to O
estimate O
the O
risk O
of O
serious O
liver O
, O
blood O
, O
skin O
, O
and O
renal O
disorders O
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

The O
risk O
of O
clinically O
important O
idiopathic O
liver O
disease O
was O
similar O
for O
persons O
prescribed O
TMP B
- I
SMZ I
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim B
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP B
- I
SMZ I
; O
of O
seven O
with O
erythema O
multiforme O
and O
Stevens O
- O
Johnson O
syndrome O
, O
four O
were O
exposed O
to O
TMP B
- I
SMZ I
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP B
- I
SMZ I
; O
of O
seven O
with O
erythema O
multiforme O
and O
Stevens O
- O
Johnson O
syndrome O
, O
four O
were O
exposed O
to O
TMP B
- I
SMZ I
. O

Efficacy O
and O
safety O
of O
granisetron B
, O
a O
selective O
5 B
- I
hydroxytryptamine I
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea O
and O
vomiting O
induced O
by O
high O
- O
dose O
cisplatin B
. O

S B
- I
312 I
, O
S B
- I
312 I
- I
d I
, O
but O
not O
S B
- I
312 I
- I
l I
, O
L O
- O
type O
calcium B
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic O
tonic O
convulsions O
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine B
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

Pulmonary O
edema O
and O
shock O
after O
high O
- O
dose O
aracytine B
- I
C I
for O
lymphoma O
; O
possible O
role O
of O
TNF O
- O
alpha O
and O
PAF O
. O

Four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
Ara B
- I
C I
for O
lymphomas O
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

Sequential O
biological O
assays O
of O
IL O
- O
1 O
, O
IL O
- O
2 O
, O
TNF O
and O
PAF O
were O
performed O
during O
Ara B
- I
C I
infusion O
to O
ten O
patients O
, O
including O
the O
four O
who O
developed O
the O
syndrome O
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock O
and O
adult O
respiratory O
distress O
syndrome O
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara B
- I
C I
may O
be O
associated O
with O
cytokine O
release O
. O

Kaliuretic O
effect O
of O
L B
- I
dopa I
treatment O
in O
parkinsonian O
patients O
. O

Hypokalemia O
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
L B
- I
dopa I
- O
treated O
parkinsonian O
patients O
. O

The O
influence O
of O
L B
- I
dopa I
on O
the O
renal O
excretion O
of O
potassium B
was O
studied O
in O
3 O
patients O
with O
hypokalemia O
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium B
and O
sodium B
as O
well O
as O
urinary O
excretion O
of O
potassium B
, O
sodium B
and O
aldosterone B
. O

L B
- I
Dopa I
intake O
was O
found O
to O
cause O
an O
increased O
excretion O
of O
potassium B
, O
and O
sometimes O
also O
of O
sodium B
, O
in O
the O
hypokalemic O
but O
not O
in O
the O
normokalemic O
patients O
. O

It O
is O
not O
known O
why O
this O
effect O
occurred O
in O
some O
individuals O
but O
not O
in O
others O
, O
but O
our O
results O
indicate O
a O
correlation O
between O
aldosterone B
production O
and O
this O
renal O
effect O
of O
L B
- I
dopa I
. O

With O
this O
model O
we O
investigated O
the O
effect O
of O
chronic O
doxorubicin B
administration O
on O
the O
ECG O
of O
freely O
moving O
BALB O
/ O
c O
mice O
and O
the O
efficacy O
of O
ICRF B
- I
187 I
as O
a O
protective O
agent O
. O

As O
this O
schedule O
exerted O
more O
toxicity O
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
ICRF B
- I
187 I
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity O
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin B
given O
i O
. O
v O
. O
plus O
2 O
weeks O
of O
observation O
) O
. O

On O
this O
schedule O
, O
the O
animals O
' O
hearts O
appeared O
normal O
after O
sacrifice O
and O
ICRF B
- I
187 I
( O
50 O
mg O
/ O
kg O
given O
i O
. O
p O
. O
1 O
h O
before O
doxorubicin B
) O
provided O
almost O
full O
protection O
. O

These O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin B
- O
induced O
cardiotoxicity O
as O
demonstrated O
by O
the O
protection O
provided O
by O
ICRF B
- I
187 I
. O

Effects O
of O
a O
new O
calcium B
antagonist O
, O
CD B
- I
832 I
, O
on O
isoproterenol B
- O
induced O
myocardial O
ischemia O
in O
dogs O
with O
partial O
coronary O
stenosis O
. O

Effects O
of O
CD B
- I
832 I
on O
isoproterenol B
( O
ISO B
) O
- O
induced O
myocardial O
ischemia O
were O
studied O
in O
dogs O
with O
partial O
coronary O
stenosis O
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine B
or O
diltiazem B
. O

After O
the O
control O
ISO B
infusion O
with O
stenosis O
was O
performed O
, O
equihypotensive O
doses O
of O
CD B
- I
832 I
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine B
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem B
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
ISO B
infusion O
. O

Both O
CD B
- I
832 I
and O
diltiazem B
, O
but O
not O
nifedipine B
, O
significantly O
reduced O
the O
increase O
in O
heart O
rate O
induced O
by O
ISO B
infusion O
. O

In O
contrast O
to O
nifedipine B
, O
CD B
- I
832 I
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
01 O
) O
and O
ST O
- O
segment O
elevation O
from O
5 O
. O
6 O
+ O
/ O
- O
1 O
. O
0 O
mV O
to O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
mV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO B
infusion O
with O
stenosis O
. O

These O
data O
show O
that O
CD B
- I
832 I
improves O
myocardial O
ischemia O
during O
ISO B
infusion O
with O
stenosis O
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD B
- I
832 I
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD B
- I
832 I
. O

These O
data O
show O
that O
CD B
- I
832 I
improves O
myocardial O
ischemia O
during O
ISO B
infusion O
with O
stenosis O
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD B
- I
832 I
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD B
- I
832 I
. O

These O
data O
show O
that O
CD B
- I
832 I
improves O
myocardial O
ischemia O
during O
ISO B
infusion O
with O
stenosis O
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD B
- I
832 I
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD B
- I
832 I
. O

Nefiracetam B
( O
DM B
- I
9384 I
) O
reverses O
apomorphine B
- O
induced O
amnesia O
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

MK B
- I
801 I
augments O
pilocarpine B
- O
induced O
electrographic O
seizure O
but O
protects O
against O
brain O
damage O
in O
rats O
. O

The O
authors O
examined O
the O
anticonvulsant O
effects O
of O
MK B
- I
801 I
on O
the O
pilocarpine B
- O
induced O
seizure O
model O
. O

Scopolamine B
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital B
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine B
- O
induced O
behavioral O
seizure O
but O
MK B
- I
801 I
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
did O
not O
. O

Scopolamine B
and O
pentobarbital B
blocked O
the O
pilocarpine B
- O
induced O
electrographic O
seizure O
, O
MK B
- I
801 I
treatment O
augmented O
the O
electrographic O
seizure O
induced O
by O
pilocarpine B
. O

Pentobarbital B
, O
scopolamine B
and O
MK B
- I
801 I
protected O
the O
brain O
damage O
by O
pilocarpine B
, O
though O
in O
the O
MK B
- I
801 I
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

Pentobarbital B
, O
scopolamine B
and O
MK B
- I
801 I
protected O
the O
brain O
damage O
by O
pilocarpine B
, O
though O
in O
the O
MK B
- I
801 I
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

Paclitaxel B
, O
5 B
- I
fluorouracil I
, O
and O
folinic B
acid I
in O
metastatic O
breast O
cancer O
: O
BRE O
- O
26 O
, O
a O
phase O
II O
trial O
. O

5 B
- I
Fluorouracil I
plus O
folinic B
acid I
and O
paclitaxel B
( O
Taxol B
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast O
cancer O
patients O
. O

Paclitaxel B
and O
5 B
- I
fluorouracil I
have O
additive O
cytotoxicity O
in O
MCF O
- O
7 O
cell O
lines O
. O

We O
performed O
a O
phase O
II O
trial O
of O
paclitaxel B
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
I O
followed O
by O
folinic B
acid I
300 O
mg O
over O
1 O
hour O
before O
5 B
- I
fluorouracil I
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
TFL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

There O
was O
no O
change O
in O
the O
levels O
of O
DA B
, O
norepinephrine B
( O
NE B
) O
, O
serotonin B
( O
5 B
- I
HT I
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia O
and O
an O
increase O

There O
was O
no O
change O
in O
the O
levels O
of O
DA B
, O
norepinephrine B
( O
NE B
) O
, O
serotonin B
( O
5 B
- I
HT I
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia O
and O
an O
increase O

Effect O
of O
D B
- I
Glucarates I
on O
basic O
antibiotic O
- O
induced O
renal O
damage O
in O
rats O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B
- I
glucarates I
, O
and O
also O
to O
other O
saccharic B
acid I
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

D B
- I
Glucarates I
were O
effective O
against O
renal O
damage O
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside B
antibitocis O
. O

Dose O
- O
responses O
were O
observed O
in O
the O
protective O
effect O
of O
D B
- I
Glucarates I
. O

With O
a O
D B
- I
glucarate I
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal O
damages O
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

D B
- I
Glucarates I
had O
the O
ability O
to O
prevent O
renal O
damage O
but O
not O
to O
cure O
it O
. O

The O
reduction O
effect O
of O
D B
- I
glucarates I
against O
nephrotoxicity O
of O
basic O
antibiotics O
was O
discussed O
. O

Sumatriptan B
succinate I
, O
a O
serotonin B
- O
1 O
( O
5 B
- I
hydroxytryptamine I
- O
1 O
) O
receptor O
agonist O
, O
is O
an O
antimigraine O
drug O
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial O
arteries O
. O

51 O
patients O
with O
medically O
refractory O
Parkinson O
' O
s O
disease O
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
August O
1993 O
and O
February O
1997 O
for O
treatment O
of O
bradykinesia O
, O
rigidity O
, O
and O
L B
- I
DOPA I
- O
induced O
dyskinesias O
. O

Differential O
effects O
of O
17alpha B
- I
ethinylestradiol I
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile B
salt I
synthesis O
in O
the O
rat O
. O

Effects O
of O
17alpha B
- I
ethinylestradiol I
( O
EE B
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile B
salt I
( O
BS B
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long O
- O
term O
bile O
diversion O
to O
induce O
BS B
synthesis O
. O

This O
study O
shows O
that O
17alpha B
- I
ethinylestradiol I
( O
EE B
) O
- O
induced O
intrahepatic O
cholestasis O
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile B
salt I
( O
BS B
) O
synthesis O
. O

The O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin B
A I
and O
nifedipine B
included O
an O
increase O
in O
blood B
urea I
nitrogen I
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival O
hyperplasia O
in O
2 O
of O
the O
13 O
patients O
. O

